Colgate-Palmolive maintains a dominant global position in oral care while diversifying its growth through a specialized pet nutrition segment.
Kimberly-Clark provides essential personal and family care products with a focus on improving margins and optimizing its global supply chain.
Which consumer staple giant is the better fit for your portfolio?
Investors often turn to reliable household brands when volatility hits the market. Choosing between Colgate-Palmolive (NYSE:CL) and Kimberly-Clark (NASDAQ:KMB) means deciding which defensive giant can absorb market shocks the best while still rewarding long-term shareholders.
Colgate-Palmolive focuses heavily on its market-leading oral care segment while expanding its reach in pet nutrition. Kimberly-Clark relies on its dominance in essential items like tissues and diapers. Both companies are staples in the retail landscape, but their differing balance sheet structures and growth strategies set them apart for investors.
Colgate-Palmolive operates as a global leader in oral care, personal care, and home care. It also owns Hill's Pet Nutrition, which serves the growing pet food market. The company sells its products through a vast network of retailers and distributors, with Walmart (NASDAQ:WMT) representing nearly 11% of its net sales. Customer concentration like this adds a layer of risk to the business.
In its latest annual report, filed for FY 2025, revenue reached nearly $20.4 billion. This represented growth of roughly 1.4% compared to the prior year. The company reported net income of approximately $2.1 billion during the same period. This sector remains popular among investors looking at consumer staples stocks.
Kimberly-Clark produces essential products for personal and family care, including brands like Kleenex and Huggies. Its business is organized across major global markets and a dedicated professional segment. Walmart is its largest customer, accounting for approximately 16% of net sales in 2025. Customer concentration like this adds a layer of risk to the business.
In its latest annual report, filed for FY 2025, revenue reached nearly $16.4 billion. This reflected a decline of roughly 2.1% from the previous year. Despite the lower top line, the company generated net income of close to $2 billion. Its net margin for this period sat at approximately 12.3%, indicating the percentage of revenue that remains as profit after all expenses.
Colgate-Palmolive faces intense global competition from other major brands and private-label products. International operations expose it to foreign currency fluctuations and geopolitical instability. The company is also subject to ongoing talc-related litigation and recently recognized an impairment charge related to its skin health business. Rivalry from Procter & Gamble (NYSE:PG) remains a constant factor in its core markets.
Kimberly-Clark faces risks from volatile raw material costs, particularly for pulp and petroleum-based materials. The company must also successfully navigate the integration of its Kenvue acquisition while fighting for market share against branded and private-label competitors. It is exposed to international market risks and potential supply chain disruptions.
Kimberly-Clark appears more attractively priced based on its lower forward price-to-earnings (P/E) ratio compared to the premium valuation given to Colgate-Palmolive.
| Metric | Colgate-Palmolive | Kimberly-Clark |
|---|---|---|
| Forward P/E | 24.3x | 14.7x |
| P/S ratio | 3.7x | 2.2 |
Stocks that have boosted their dividend payouts for 50 or more consecutive years are considered Dividend Kings, and both Colgate-Palmolive and Kimberly-Clark have earned that title. Colgate-Palmolive has increased its dividend payout for 64 consecutive years, while Kimberly-Clark has increased its dividend payout for 54 consecutive years. In that regard, both are reliable companies, and they've shown that their business models are strong, as the ability to keep boosting dividends that long is no small task.
Still, between the two, the difference boils down to whether an investor believes Colgate-Palmolive can be more successful with a growing portion of its revenue coming from pet food, or whether Kimberly-Clark can be more successful with an expanded portfolio of hygiene and health products, thanks to its recent acquisition of Kenvue. That acquisition now puts Tylenol, Band-Aid, and Neutrogena, just to name a few brands, under the Kimberly-Clark umbrella. The long-term risk, however, is that the Kenvue acquisition won't deliver the synergy Kimberly-Clark expected.
In comparison, Colgate-Palmolive's Hill's Pet Nutrition brand generated a whopping $1.2 billion in the third quarter of 2026, increasing 5.5% from the prior-year period. That accounted for 22% of the company's total sales. That pairs a potential revenue growth engine in pet food for the company with its steady oral, personal, and home care segment, which generated $4.1 billion in the third quarter.
Before you buy stock in Colgate-Palmolive, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Colgate-Palmolive wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 15, 2026.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Colgate-Palmolive and Walmart. The Motley Fool recommends Kimberly-Clark. The Motley Fool has a disclosure policy.